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Objective: To evaluate the sponsored centers for clinical trial in the respiratory 
care setting in Brazil: profile; logistics and structure. 
Methods: Principal investigators (29) and subinvestigators (30) of 39 research 
centers completed the questionnaires that addressed personal identification and 
training of researchers, the centers’ facilities and advantages and/or disadvan-
tages of performing sponsored trials. 
Results: 75.6% of the centers were located in southern and southeastern Brazil. Most 
principal investigators were men with a mean age of 53.4 years. The clinical trials in 
the respiratory care setting focus on asthma and chronic obstructive pulmonary 
disease (COPD). 80% of the researchers cited delay of the Conep and Anvisa as a bar-
rier to performing research. The advantages of participating in clinical trials were 
updating knowledge of the researcher and the team, and additional income for the 
team. The main disadvantages mentioned by the researchers included low financial 
compensation for the performed workload, and time availability. The median num-
ber of professionals per research center was six people, predominantly physicians. 
Conclusion: The number of research centers in the respiratory care setting in 
Brazil is still relatively small. The teams have good training for performing the 
clinical trials. Asthma and COPD are the most studied diseases in sponsored 
clinical trials. The main barrier is delay by the Conep and Anvisa. The factors that 
lead investigators to participate range from being updated along with the team, 
to site and staff financial issues; the main disadvantage is the low compensation 
for the required workload demand.
Keywords: Biomedical research, drug industry, clinical trials as topic.
introduction
Clinical research is a term that refers to investigations in 
humans regarding a specific therapy or new procedures, 
their effects, safety, tolerability and efficacy. These sur-
veys are usually sponsored by pharmaceutical companies 
who have developed the new drug or procedure, and which 
manage the process of conducting research, or hiring spe-
cialized companies, called clinical research Organizations 
(CRO). The goal is to ensure that these studies meet the 
international standards recommended by regulators and 
controllers, according to the International Conference 
on Harmonization/Good Clinical Practice (ICH/GCP),1,2 
the Good Clinical Practice Guidelines3,4 and the Docu-
ment of the Americas elaborated by the Pan American 
Health Organization (PAHO).5
The first resolution on clinical research in Brazil was 
CNS Resolution 01/1988, demarcating the ethical aspects 
that should be followed for conducting research in the 
health sector in the country.6 It was followed by Resolu-
tion 196/1996, entitled Guidelines and Norms Regulat-
ing research Involving Human Beings.7
The exponential growth of clinical research in Brazil 
is undeniable, also in the area of pulmonology, creating 
a market that intertwines various aspects. This growth 
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stems from greater awareness of the prevalence of respi-
ratory diseases and chronic diseases in general8 in the 
country and specifically in the respiratory area, as well as 
the number of new drugs that are being developed for 
asthma,9 chronic obstructive pulmonary disease,10 pulmo-
nary fibrosis and pulmonary hypertension.11 Experience 
has shown that centers initially associated with sponsored 
clinical research, those sponsored by the pharmaceutical 
industry, have started to perform academic research. How-
ever, little is known about the teams and research centers 
that are involved in carrying out sponsored multicentric 
clinical research in pulmonology. Knowledge about the 
teams and pulmonology research centers in our country 
and their dissemination could encourage the creation of 
other centers.
The primary objective of this study was to delineate 
the profile of sponsored multicentric clinical research 
centers in the respiratory area in Brazil, assessing the phys-




Two questionnaires were developed related to sponsored 
clinical research, one for the principal investigators and 
another for physicians acting as subinvestigators. As in-
clusion criteria, the respondents had to be a principal in-
vestigator and/or subinvestigator at a center working in 
the respiratory area. As this research would not cause any 
moral, financial or psychological harm, the research Eth-
ics Committee (REC)/Unifesp (registration number 
1044/09) advised that by simply answering the question-
naire the investigators implied that they agreed with the 
research, so a consent form was not required.
Preparation of questionnaires
The questions related to the identification, training of re-
spondents, the premises of the centers and advantages 
and disadvantages regarding participation in sponsored 
clinical research were common to both questionnaires. 
Questions about the physical facilities of the center, the 
team’s constituents and financial aspects were answered 
only by the principal investigators.
Most of the questions were closed. In addition to these, 
open questions were elaborated, which allowed the respon-
dent to answer freely by giving their opinion. The princi-
pal investigator questionnaire contained 36 questions, 24 
closed and 12 open, while the subinvestigator question-
naire contained 22 questions, 11 closed and 11 open.
Questionnaires
The participating principal investigators and subinves-
tigators received an electronic message with an invita-
tion letter explaining the study. A link was provided 
that led to a page available on the Unifesp website, which 
contained the two questionnaires. Each investigator 
answered the questionnaire that was specific to them. 
Respondents sent the answers electronically, which were 
automatically stored in a database specifically devel-
oped for this research. The minimum sample size could 
not be calculated because this was a descriptive study. 
All of the pulmonologists who were principal investi-
gators and subinvestigators at sponsored research cen-
ters working in the respiratory area in Brazil were in-
vited from the list of centers specialized in conducting 
clinical research in the respiratory area from the Clin-
ical Research Organizations (CROs) and sponsoring 
pharmaceutical industries. Data collection, including 
sending the invitation and link to the questionnaire, 
took place during the period between December 2010 
and June 2011.
Statistical analysis
The numerical data is displayed as mean, median and 




Thirty-nine centers were initially included. Twenty-nine 
principal investigators (61.7%) and thirty subinvestiga-
tors (57.7 %) of a total of 43 principal investigators and 
52 subinvestigators responded the questionnaires. Up to 
four attempts were made to contact researchers who did 
not respond to the first request. The overall non-response 
rate was 37.9%. The predominant reason for not accept-
ing the invitation was “lack of time to answer the ques-
tionnaire”.
Characterization of the sample – characterization of clinical re-
search centers
Given the total number of research centers, 55.1% are in 
the southeast and 20.6% in the south of Brazil. São Pau-
lo leads with 37.9%. The northeast and midwest regions 
represent only 10.3% and 3.4%, respectively. The north re-
gion did not have a clinical research center working in 
the respiratory area in Brazil (Figure 1). Most of the re-
search centers (62%) operated in public teaching institu-
tions (24.1%) or public hospitals (37.9%).
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Characteristics of the sample of principal investigators and 
subinvestigators
The demographic characteristics and training of research-
ers are shown in Table 1.
TABLE 1 Characteristics of the sample of investigators 
and subinvestigators of the study (n = 59).




Age – years (SD) 53.4 (8.0) 37.4 (7.2)
Age range – n (%)
20–29  – 2 (6.7 )
30–39 2 (6.8) 19 (63.3 )
40–49 7 (24.2) 8 (26.7 )
50–59 12 (41.4) 1 (3.3 )
60–69 8 (27.6)  –
Gender – n (%)
Male 20 (68.7) 11 (36.7)
Female 9 (31.3) 19 (63.3)
Years of profession 
– years (SD)
28.4 (8.4) 13.1 (7.6)
Graduate diploma – n (%)
Specialized in clinical 
research * – n (%)
7 (24.1) 9 (30)
Medical residency 28 (96.6) 27 (90.0)
MSc 18 (62.1) 11 (36.7)
PhD 21 (72.4) 9 (30.0)
Post–doctoral 11 (37.9) 3 (10.0)
Professor/preceptor 
– n (%)
24 (82.8) 14 (46.7)
Thesis supervision –  
n (%)
19 (65.5) 3 (10.0)
SD: Standard deviation.
*Continuing education in Good Clinical Practice (GCP) and/or short courses.
Areas of greatest activity of the sponsored clinical research
The areas of greatest activity in active research centers 
were asthma and chronic obstructive pulmonary disease 
(COPD), followed by oncology, infection, pulmonary cir-
culation and interstitial diseases, respectively.
Difficulties reported for conducting sponsored clinical research 
in the respiratory area in Brazil
The researchers indicated the National Ethics and re-
search Commission (Conep) and the National Health 
Surveillance Agency (Anvisa) as the main difficulties for 
conducting research, mainly in the “delay” item (Table 2). 
Difficulty of recruiting patients was also reported. With 
regard to the team, the main item was the required “time 
available”.
TABLE 2 Difficulties reported for conducting clinical 
research in Brazil.





Conep – n (%) 24 (82.7) 24 (80.0)
Delay 22 (91.6) 24 (100.0)
Demands 9 (37.5) 9 (37.5)
Lack of training 6 (25.0) 6 (25.0)
Anvisa – n (%) 21 (72.4) 14 (46.6)
Delay 19 (90.4) 14 (100.0)
Demands 10 (47.6) 6 (42.8)
Lack of training 5 (23.8) 2 (14.3)
CEP – n (%) 9 (31.0) 7 (23.3)
Delay 9 (100.0) 5 (71.4)
Demands 3 (33.3) 5 (71.4)
Lack of training 2 (22.2) 1 (14.3)
Patients – n (%) 12 (41.37) 20 (66.6)
Difficulty recruiting 9 (75.0) 15 (75.0)
Cognition 8 (66.6) 9 (45.0)
Low adherence 4 (33.3) 11 (55.0)
Illiteracy 8 (66.6) 4 (20.0)
Center infrastructure 2 (16.6) 8 (40.0)
Team – n (%) 11 (37.9) 8 (30.0)
Time availability 9 (81.8) 5 (55.5)
Profession regulations 6 (54.5) 3 (33.3)
Note: In some of the variables, the sum of the sub-items may have a number of responses gre-
ater than the total number of investigators because they could respond to more than one item.
The main advantages in participating in clinical research 
indicated by principal investigator were “additional in-
come for the team” and “funding for the center/institu-
tion”, both with 86.2%.
Characterization of the research center teams
The questionnaire directed to principal investigators con-
tained questions related to the characterization of their 
research center, including positions and professions ex-
isting at the center.
The median number of professionals by research cen-
ter was six people, with a percentile of 25/75% for 4/6 per-
sons, and predominantly physicians.
Of the total of 40 research coordinators reported, the 
highest proportion was that of physiotherapists (32.5%), 
even though they were not in greater numbers. In research 
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assistance, five of the 13 professionals (38.5%) were nurs-
es and three (23.1%) were pharmacists.
discussion
This assessment has shown that there are still few active 
research centers in Brazil in the respiratory area compared 
with the international context. However, the centers are 
relatively well structured in relation to basic infrastruc-
ture, and the academic training of the team involved is 
good. The main obstacles to research are external to the 
center, and are associated with authorities such as the 
Conep and Anvisa, due to delay in the analysis and clear-
ance of projects. The factors that lead the centers to do 
research are multiple, including updating the knowledge 
of the team, finance and links to other research centers. 
Lastly, we found that the main disadvantages are the lim-
ited time availability and low payment offered by the in-
dustry for conducting clinical research.
While sending the questionnaire, we observed the ex-
istence of a small number of active research centers in our 
country in the area of respiratory medicine compared to 
the number of research centers in Europe, the United 
States and even other countries in Latin America, such 
as Argentina, which presented a greater number of cen-
ters at the time. In addition, these centers were concen-
trated in the southeast and south regions of the country, 
with only two centers in the northeastern region, in the 
states of Bahia and Pernambuco, and one in the midwest, 
in the state of Goiás. This disparity demonstrates the low 
interest in clinical research in the other regions of the 
country, which apparently has a direct relation with not 
conducting research in general, as well as poor promo-
tion of the research practice and of all the advantages to 
both the professional involved and the research institu-
tion. We did not find references to the research centers 
operating in the respiratory area in Brazil in publications 
from the United States or Europe; however, in the Torch 
Study,12 which evaluated the survival of 6,000 patients 
with COPD by comparing the use of salmeterol and fluti-
casone in association or individually, there was a partic-
ipation of 184 US centers and 156 European centers, com-
pared with 10 centers in Latin America, seven from Brazil 
and three from Argentina. In the Uplift Study,13 that mon-
itored the progression of the pulmonary function in six 
thousand COPD patients for four years, with and with-
out the use of tiotropium, 96 centers in the United States 
took part, as well as 293 centers in Europe, and in Latin 
America, only Brazil and Argentina participated in this 
study with 10 and 15 centers each, respectively. These fig-
ures demonstrate that there are still few research centers 
in Latin America compared to Europe and the United 
States.
We believe that the predominance of male investiga-
tors has no direct relation to clinical research, and is a 
characteristic of this particular sample. The principal in-
vestigators have more years of training than the subin-
vestigators, because, having worked longer in both the 
clinical practice and the academic area, they are more rec-
ognized professionally and, thus, more often invited to 
contribute by the industry.
The principal investigators and subinvestigators most-
ly have a good level of training, and are directly or indi-
rectly involved with academic research. We observed that 
the professionals involved in conducting sponsored clin-
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ical research are well qualified. They are scholars by choice 
and, to a certain extent, form a basis for the good con-
duction of clinical research.
The areas cited more frequently were COPD and asth-
ma, which is understandable, as they are the most com-
mon diseases in the respiratory area and generate great-
er financial returns, often becoming the industry’s focus 
for investment in studies.
At the ClinicalTrials.gov website, a service from the 
US National Institutes of Health comprising a registry 
and database of the results of private and public studies 
being performed throughout the world, the results cor-
roborate those found in our study.14 Obstructive pulmo-
nary diseases occupy the top position in the ranking of 
diseases studied, with 3,116 articles registered, as well as 
asthma with 1,869 studies, and COPD with 1,313 stud-
ies. The ClinicalTrials.gov website was accessed in Febru-
ary 2012 for the purpose of this article.
Despite the good training of the teams and the pro-
fessionalism in conducting studies, there are external bar-
riers to conducting clinical research in Brazil. For the in-
vestigators, the Conep and Anvisa lead the ranking of 
these difficulties, especially for the delay in the release of 
opinions. Although not cited by our sample, to be fair, it 
is worth pointing out that we also have to account for 
possible “internal barriers”, that is, those inherent to re-
search centers, such as incomplete dossiers and regulato-
ry documents completed incorrectly. These facts are of-
ten reported by officers of the Conep and Anvisa in 
meetings discussing the researcher/Conep/Anvisa rela-
tionship.
The Brazil platform launched in January 2012 and 
seen as an achievement is a national, unified database of 
research records involving humans for the entire CEP/
Conep system. It allows the follow-up of studies at dif-
ferent stages, from submission to final approval by the 
CEP and Conep. Documents are presented digitally in 
this system. One advantage of this system is that it allows 
access to everyone involved in the research, regardless of 
the location of the centers, and the Brazil Platform in-
tends to significantly reduce project processing time 
throughout the CEP/Conep system.15
Once aware of the difficulties faced in clinical research, 
as discussed above, it was important to understand what 
leads an investigator to become interested in conducting 
clinical research in Brazil. An interesting point is that we 
expected our sample to cite more openly the advantages 
related to the benefits of clinical research for patients, but 
this only occurred in 45% of our sample. In areas such as 
oncology and inflammatory diseases, patients who par-
ticipate in studies for new drugs for their illnesses bene-
fit from it, because sometimes there is still no other ther-
apy available;16 Danesi and Goldbaum17 point out that 
“about two billion people in the world are in need of es-
sential drugs”, which should be the responsibility of the 
State, although the pharmaceutical industry shares this 
responsibility through the development of new drugs 
which, in its own way, has contributed to advances in the 
quality of life of patients.17 However, the main attractions 
indicated by the researchers in our sample were: updat-
ing their knowledge and that of the team involved, addi-
tional income for the team, maintaining ties with nation-
al and international industry, funding for the center/
institution, ties with international research centers and 
access to medication and devices not available in Brazil. 
The factors above were cited more than 65% for each sam-
ple, including principal investigators and subinvestiga-
tors, given that the two most significant citations were 
“additional income for the team” and the “funding for the 
center/institution”, both with 86.2%, as shown in the re-
sults. This data exposes the Brazilian reality of low fund-
ing and limited support for Scientists involved with re-
search in general. Thus, sponsored clinical research has 
become a means of keeping a team that likes sponsored 
research, but that also conducts academic research, and 
which has in such work, in addition to the financial sup-
port, the possibility of access to knowledge, medication 
and devices that are unlikely to be available in Brazilian 
public health care and professional training institutions.
However, there are disadvantages to this participa-
tion, as confirmed by the Investigators. The main disad-
vantage is the demand for time and involvement of these 
professionals, given the standardization and national and 
international rules that permeate the development of re-
search, and the low financial compensation received in 
face of the demands of the work, that is, what is left for 
payment of the principal investigator after deducting the 
total cost of the research Center. It is not uncommon to 
find large disparities between national and internation-
al budgets, generating lower income for national centers 
and lower pay for researchers, who supplements their in-
come with other activities parallel to the research. It is 
worth reiterating that opening a research center in Bra-
zil can be more expensive, depending on its location. In 
Europe and especially in the US, non-investigational ex-
ams and medication are reimbursed by health insurance, 
while in Brazil the companies usually charge for every-
thing. More recently, the issue of supplying medication 
after the end of the research has also been adding costs 
that other countries do not face. Also, in Brazil, research-
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ers/research center managers must do their own cost stud-
ies, thereby basing their discussion with the industry on 
the negotiation of contracts.
In the characterization of the participating team, we 
observed that the centers are already well-developed with 
regard to human resources, with an average of six people 
on the team, when commonly a research center starts 
with only three people. What we observed is that the in-
crease in projects requires more professionals to assume 
the positions of Coordinators, research Assistants, and 
subinvestigators, increasing the capacity for work when 
conducting research. As expected, there is a larger pro-
portion of physiotherapists as study coordinators. We 
suppose that this occurs due to the nature of their spe-
cialty, which commonly treats patients in specialist respi-
ratory outpatient clinics working together with physi-
cians. This ends up characterizing the teams in research 
centers, with physicians and physiotherapists in the po-
sitions of principal investigators and coordinators, re-
spectively.  We also noted that, in the practice of clinical 
research, teams are formed based on familiarity, conve-
nience and affinities.
liMitations of the study
From the beginning, we intended to use the same ques-
tionnaire to know the opinion of non-specialists in the 
respiratory medicine and other physicians who do not 
participate in this type of research (from the same cities 
of the researchers) on sponsored clinical research. We re-
quested the principal investigators interviewed in our re-
search to indicate a clinician known to them and when 
contacting them we made reference to such indication. 
Unfortunately, even with this we had a very low return of 
the 26 questionnaires sent and re-sent three times again. 
Given that we received only three responses, we decided 
not to draw any conclusions from these questionnaires.
This is the first study assessing the panorama of clin-
ical research conducted in the respiratory area in Brazil. 
From this information we were able to portrait the struc-
ture of these centers, the level of training of the partici-
pating professionals and the losses and gains derived from 
this participation. It would be very interesting in the fu-
ture to conduct the same search in other areas of medi-
cine, which would provide a chance to understand more 
fully sponsored clinical research in Brazil.
This data allows us to affirm that it is possible to in-
vest in greater professionalization in this area, and we can 
no longer ignore the fact that clinical research has be-
come another possibility of working with good direct and 
indirect gains for the professionals involved and for so-
ciety in general. It is worth mentioning that over the years 
some companies have created research courses with the 
goal of leveraging training in the clinical research area.18 
However, at professional congresses of the clinical re-
search area held by the Brazilian Society of clinical re-
search Professionals (SBPPC), we have noted that inter-
est in these courses has recently been falling, probably 
due to the decrease of research center teams as a result of 
internal and external obstacles in the regulatory process 
for conducting clinical trials.
conclusion
There are few centers in Brazil in the respiratory area con-
ducting sponsored research; the teams comprise profes-
sionals with satisfactory training; the external barriers 
are mainly associated with the higher regulatory instanc-
es, the Conep and Anvisa. There are advantages that en-
courage investigators to participate in clinical research: 
updating their knowledge and that of the team involved, 
additional income for the team, national and interna-
tional links with industry, funding for the research cen-
ter or institution where it is located and, lastly, maintain-
ing and/or creating links with international research 
centers. Nevertheless, there are disadvantages, such as the 
demands of the work associated with insufficient bud-
getary remuneration.
resuMo
Pesquisas clínicas multicêntricas patrocinadas realizadas 
na área respiratória no Brasil – Perdas e ganhos
Objetivo: avaliar nos centros de pesquisas clínicas patro-
cinadas na área respiratória no Brasil o perfil, a logística 
e a estrutura. 
Método: questionários foram respondidos por pesquisa-
dores principais (29) e subinvestigadores (30) de 39 centros 
de pesquisa relativos a identificação e formação dos pesqui-
sadores, instalações dos centros e vantagens e desvantagens 
quanto à participação nas pesquisas patrocinadas. 
Resultados: setenta e cinco por cento (75,6%) dos cen-
tros se localizavam nas regiões Sul e Sudeste do Brasil. A 
maioria dos investigadores principais eram homens com 
média de idade de 53,4 anos. As pesquisas na área respi-
ratória se concentravam no estudo da asma e da doença 
pulmonar obstrutiva crônica (DPOC). Oitenta por cen-
to dos pesquisadores citaram a demora na Comissão Na-
cional de Ética em Pesquisa (Conep) e na Agência Nacio-
nal de Vigilância Sanitária (Anvisa) como fator de 
entrave para a realização das pesquisas. As vantagens em 
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participar das pesquisas clínicas foram a atualização pró-
pria ou da equipe envolvida, com rendimento adicional 
para a equipe. A principal desvantagem apontada pelos 
pesquisadores foi a baixa compensação financeira em re-
lação ao volume de trabalho e disponibilidade de tempo. 
A mediana de profissionais por centro de pesquisa foi de 
seis pessoas, com predominância de médicos. 
Conclusão: o número de centros na área respiratória no 
Brasil ainda é relativamente pequeno. As equipes apre-
sentam boa formação para a realização das pesquisas. 
Asma e DPOC são as doenças mais estudadas pelas pes-
quisas clínicas patrocinadas. O principal entrave é a de-
mora da Conep e da Anvisa. Os fatores que levam os in-
vestigadores a participarem variam desde atualização 
própria/equipe até questões financeiras para a equipe e o 
centro; a principal desvantagem relatada é a baixa remu-
neração diante da demanda de trabalho exigida.
Palavras-chave: pesquisa biomédica, indústria farmacêu-
tica, ensaios clínicos como assunto.
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